NIAID describes challenges, prospects for an HIV vaccineAugust 28, 2008WHAT: Events of the past year in HIV vaccine research have led some to question whether an effective HIV vaccine will ever be developed. In the August 28 edition of the New England Journal of Medicine, officials from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, examine the extraordinarily challenging properties of the virus that have made a vaccine elusive and outline the scientific questions that, if answered, could lead to an effective HIV vaccine. In recent years, the most extensively studied HIV vaccines have aimed to mobilize immune cells called T cells, write Anthony S. Fauci, M.D., NIAID director, and Margaret I. Johnston, Ph.D., director of the Vaccine Research Program in NIAID's Division of AIDS. T-cell vaccines are not expected to prevent HIV infection. Rather, they could potentially reduce the level of virus (but not eliminate it) following infection, limit the number of immune cells that HIV destroys, and thus delay the progression to AIDS. There is no evidence yet that T-cell HIV vaccines work in humans, however. If the vaccines ultimately do, their effectiveness may vary greatly depending on the genetic make-up of each individual, given that T-cell immunity is dependent on genetic factors. Furthermore, because the virus would persist in the blood of vaccinated individuals, T-cell vaccines would likely generate only transient "herd immunity"--that is, population-wide protection from disease conferred by vaccination of a percentage of the community. In response to the failure last September of a T-cell vaccine for which many people had high hopes, the HIV vaccine field has undergone a self-reexamination and has determined that the balance between fundamental discovery research and product development should shift toward discovery. In particular, future research must intensify the study of broadly neutralizing antibodies to HIV, why most HIV-infected people do not make them, and the design of novel strategies to induce them with a vaccine. Also, studying the earliest stages of HIV infection may shed light on ways to manipulate innate and mucosal immune responses to widen the window of opportunity for viral eradication, to prevent the virus from advancing to gut-associated lymphoid tissue, or both.
The authors conclude with cautious optimism that an effective HIV vaccine will be developed, but will depend on the significant growth of scientific understanding of HIV disease and human responses to the virus. NIH/National Institute of Allergy and Infectious Diseases | |||||||||||||||||||||
|
Related Hiv Vaccine Current Events and Hiv Vaccine News Articles Results of landmark study of HIV vaccine published in the Lancet Results from the Step study, a test-of-concept efficacy study of a Merck & Co., Inc. HIV vaccine candidate, were published online today in two papers in The Lancet. These analyses of the Step study are being conducted, presented and published to inform the continued search for an effective HIV vaccine. How HIV vaccine might have increased odds of infection In September 2007, a phase II HIV-1 vaccine trial was abruptly halted when researchers found that the vaccine may have promoted, rather than prevented, HIV infection. UT Pathologists Believe They Have Pinpointed Achilles Heel of HIV Human Immunodeficiency Virus (HIV) researchers at The University of Texas Medical School at Houston believe they have uncovered the Achilles heel in the armor of the virus that continues to kill millions. HIV Infection Stems From Few Viruses A new study reveals the genetic identity of human immunodeficiency virus (HIV), the version responsible for sexual transmission, in unprecedented detail. Exhaustion of HIV-specific T cells may be caused by chronic exposure to virus The "exhaustion" of immune cells that target HIV appears to result from chronic exposure to the virus, specifically exposure to the particular protein segments targeted by the pathogen-killing HIV-specific CD8 T cells. Scripps research scientists devise approach that stops HIV at earliest stage of infection Researchers at The Scripps Research Institute have developed a new two-punch strategy against HIV and they have already successfully tested aspects of it in the laboratory. Nanoemulsion vaccines show increasing promise A novel technique for vaccinating against a variety of infectious diseases - using an oil-based emulsion placed in the nose, rather than needles - has proved able to produce a strong immune response against smallpox and HIV in two new studies. New insights into vaccination for HIV A group of Australian researchers at the Universities of Melbourne and New South Wales have developed new tools and paradigms to understand immune evasion from HIV. Keeping young South Africans in school: A 'social vaccine' against AIDS A study published today in the Journal of Epidemiology and Community Health suggests that secondary school attendance is linked to lower risk of HIV infection among young people in rural South Africa. Uncovering the Achilles' heel of the HIV-1 envelope New structural details illustrate how a promising class of antibodies may block human immunodeficiency virus (HIV)-1 infection and reveal valuable clues for design of an effective HIV-1 vaccine. More Hiv Vaccine Current Events and Hiv Vaccine News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||